Toll Free: 1-888-928-9744

Immunocore Limited - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 33 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Immunocore Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Immunocore Limited - Product Pipeline Review - 2015', provides an overview of the Immunocore Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunocore Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunocore Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunocore Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunocore Limited's pipeline products

Reasons to buy

- Evaluate Immunocore Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunocore Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunocore Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunocore Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunocore Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Immunocore Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Immunocore Limited Snapshot 5 Immunocore Limited Overview 5 Key Information 5 Key Facts 5 Immunocore Limited - Research and Development Overview 6 Key Therapeutic Areas 6 Immunocore Limited - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 Pipeline Products - Partnered Products 10 Partnered Products/Combination Treatment Modalities 11 Immunocore Limited - Pipeline Products Glance 12 Immunocore Limited - Clinical Stage Pipeline Products 12 Phase I Products/Combination Treatment Modalities 12 Immunocore Limited - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 Discovery Products/Combination Treatment Modalities 14 Immunocore Limited - Drug Profiles 15 IMCgp100 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 IMCmage1 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Recombinant Protein for Cancer 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Recombinant Protein for HCV 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Recombinant Protein for Prostate Cancer 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Recombinant Protein for Type I Diabetes 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Recombinant Protein to Antagonize CD3 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Recombinant Protein to Inhibit Gag for HIV 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Immunocore Limited - Pipeline Analysis 24 Immunocore Limited - Pipeline Products by Target 24 Immunocore Limited - Pipeline Products by Route of Administration 25 Immunocore Limited - Pipeline Products by Molecule Type 26 Immunocore Limited - Pipeline Products by Mechanism of Action 27 Immunocore Limited - Recent Pipeline Updates 28 Immunocore Limited - Dormant Projects 30 Immunocore Limited - Locations And Subsidiaries 31 Head Office 31 Appendix 32 Methodology 32 Coverage 32 Secondary Research 32 Primary Research 32 Expert Panel Validation 32 Contact Us 32 Disclaimer 33
List of Tables
Immunocore Limited, Key Information 5 Immunocore Limited, Key Facts 5 Immunocore Limited - Pipeline by Indication, 2015 7 Immunocore Limited - Pipeline by Stage of Development, 2015 8 Immunocore Limited - Monotherapy Products in Pipeline, 2015 9 Immunocore Limited - Partnered Products in Pipeline, 2015 10 Immunocore Limited - Partnered Products/ Combination Treatment Modalities, 2015 11 Immunocore Limited - Phase I, 2015 12 Immunocore Limited - Preclinical, 2015 13 Immunocore Limited - Discovery, 2015 14 Immunocore Limited - Pipeline by Target, 2015 24 Immunocore Limited - Pipeline by Route of Administration, 2015 25 Immunocore Limited - Pipeline by Molecule Type, 2015 26 Immunocore Limited - Pipeline Products by Mechanism of Action, 2015 27 Immunocore Limited - Recent Pipeline Updates, 2015 28 Immunocore Limited - Dormant Developmental Projects,2015 30



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify